Camurus AB
CAMRF
Other OTC60.00
USD
-1.01
- -
ISIN
SE0007692850
CUSIP
13217Q105
Return %
Stock
S&P500
1Y
-4.76
19.99
3Y
175.10
69.40
5Y
365.12
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sven Fredrik Tiberg
- Full Time Employees
- 277
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Ideon Science Park Lund CAM Sweden 223 70
- IPO Date
- Dec 11, 2017
- Website
- camurus.com
- Similar Companies
- Business
- Camurus AB (publ) (Nasdaq Stockholm: CAMX) is a Swedish science-led biopharmaceutical company that develops and commercializes innovative, long-acting medicines for patients with severe and chronic diseases, including opioid dependence, pain, cancer, endocrine disorders, rare diseases and supportive care; the company leverages its proprietary FluidCrystal drug delivery technology platform to create sustained-release formulations such as weekly and monthly subcutaneous depots. Core products on the market include Buvidal (buprenorphine prolonged-release injection) for opioid dependence, marketed in Europe, Australia and other regions through commercial partnerships; Brixadi (buprenorphine) extended-release subcutaneous injection for opioid use disorder in the US, distributed by partner Braeburn Pharmaceuticals; and Oczyesa (octreotide subcutaneous depot) for acromegaly and neuroendocrine tumours. The clinical pipeline features candidates like CAM2029 (octreotide depot) in phase 3 for neuroendocrine tumours and acromegaly, CAM2056 (semaglutide monthly depot) with positive topline phase 1 data for cardiometabolic diseases, CAM2038 (buprenorphine depot) for chronic pain, and programs in oncology and rare diseases developed in-house or with partners. Founded in 1991 and headquartered in Lund, Sweden, Camurus employs over 275 people with regional offices in the UK, Germany, Australia and the US; it operates primarily in Europe, North America and Australia. Recent developments include EU and UK approvals for Oczyesa in acromegaly (July 2025), UK launch of Oczyesa (November 2025), a June 2025 license and collaboration agreement with Eli Lilly for long-acting FluidCrystal incretins in cardiometabolic disease (with up to SEK 870m milestones plus royalties, excluding Camurus' independent semaglutide program), positive topline results from the CAM2056 phase 1 study (November 2025), and POSITANO phase 2b data for CAM2029 in polycystic liver disease (June 2025).
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Camurus announces expansion of Lilly collaboration
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
US FDA declines to approve Camurus' rare hormone disorder drug
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl